非小细胞肺癌靶向治疗的突破。
Breakthrough in targeted therapy for non-small cell lung cancer.
机构信息
Southern Marine Science and Engineering Guangdong Laboratory (Zhanjiang), Zhanjiang, China; Guangdong Key Laboratory for Research and Development of Natural Drugs, The Marine Biomedical Research Institute, Guangdong Medical University, Zhanjiang, China.
Southern Marine Science and Engineering Guangdong Laboratory (Zhanjiang), Zhanjiang, China; Guangdong Key Laboratory for Research and Development of Natural Drugs, The Marine Biomedical Research Institute, Guangdong Medical University, Zhanjiang, China; The Key Lab of Zhanjiang for R&D Marine Microbial Resources in the Beibu Gulf Rim, Guangdong Medical University, Zhanjiang, China; The Marine Biomedical Research Institute of Guangdong Zhanjiang, Zhanjiang, China.
出版信息
Biomed Pharmacother. 2021 Jan;133:111079. doi: 10.1016/j.biopha.2020.111079. Epub 2020 Dec 4.
Non-small cell lung cancer (NSCLC) remains by far the single most common malignancy of lung cancer which causes more and more mortality in recent years. NSCLC accounts for more than 80 % of lung cancers, and the vast majority of patients were found to be in advanced inoperable stages. Chemotherapy used to be the main treatment for NSCLC, but due to its obvious side effects. Chemotherapy gradually withdrew from the stage of history. In recent years, cellular and molecular biotechnology has developed rapidly, and researchers have begun to target key genes and regulatory molecules for treatment. Targeted drugs have also emerged. The purpose of this review is to introduce important research achievements in recent years and the treatment progress of new drugs.
非小细胞肺癌（NSCLC）仍然是目前最常见的肺癌类型，近年来导致了越来越多的死亡。NSCLC 占肺癌的 80%以上，绝大多数患者被发现处于晚期不可手术阶段。化疗曾是 NSCLC 的主要治疗方法，但由于其明显的副作用，化疗逐渐退出了历史舞台。近年来，细胞和分子生物技术发展迅速，研究人员开始针对关键基因和调节分子进行治疗。靶向药物也随之出现。本文旨在介绍近年来的重要研究成果和新药的治疗进展。
Zotero 插件